XNCR Stock Overview
A clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xencor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.29 |
| 52 Week High | US$27.24 |
| 52 Week Low | US$15.31 |
| Beta | 0.70 |
| 1 Month Change | -2.88% |
| 3 Month Change | 22.93% |
| 1 Year Change | 14.58% |
| 3 Year Change | -40.19% |
| 5 Year Change | -29.37% |
| Change since IPO | 191.25% |
Recent News & Updates
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Dec 03
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 10Xencor: Vudalimab Development Along With Hidden Gem Candidate
Sep 12Recent updates
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Dec 03Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 10Xencor: Vudalimab Development Along With Hidden Gem Candidate
Sep 12Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Sep 12Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Sep 06Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
Jul 13Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
Jun 16Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Mar 27There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Feb 27Xencor: Standing Out With XmAb Technology
Feb 03Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
Jan 05Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
Nov 13Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
Nov 10Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Aug 08Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon
Aug 12Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M
Aug 03Xencor: Capital-Efficient Platform Tech Play With A Lot Going On
Jun 03Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate
Feb 18Shareholder Returns
| XNCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -3.3% | -2.2% |
| 1Y | 14.6% | -1.9% | 23.9% |
Return vs Industry: XNCR exceeded the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: XNCR underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| XNCR volatility | |
|---|---|
| XNCR Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XNCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XNCR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 280 | Bassil Dahiyat | www.xencor.com |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.
Xencor, Inc. Fundamentals Summary
| XNCR fundamental statistics | |
|---|---|
| Market cap | US$1.70b |
| Earnings (TTM) | -US$198.24m |
| Revenue (TTM) | US$85.16m |
20.0x
P/S Ratio-8.6x
P/E RatioIs XNCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XNCR income statement (TTM) | |
|---|---|
| Revenue | US$85.16m |
| Cost of Revenue | US$239.68m |
| Gross Profit | -US$154.51m |
| Other Expenses | US$43.73m |
| Earnings | -US$198.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | -181.43% |
| Net Profit Margin | -232.77% |
| Debt/Equity Ratio | 2.5% |
How did XNCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:13 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xencor, Inc. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Zhiqiang Shu | Berenberg |
| Etzer Darout | BMO Capital Markets Equity Research |